Jazz Pharmaceuticals

Update in progress

JAZZ (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Jazz Pharmaceuticals identifies, develops, and commercializes medicines worldwide. It markets Xywav for narcolepsy with cataplexy or excessive daytime sleepiness, Epidiolex for seizures in LGS, DS, or TSC, Rylaze for ALL/lymphoblastic lymphoma, Enrylaze for ALL/LBL, Zepzelca for metastatic small cell lung cancer, Ziihera for HER2-positive biliary tract cancers, Modeyso for H3 K27M diffuse midline glioma, and Defitelio for severe veno-occlusive disease. It runs additional Phase 3 and Phase 2 programs and collaborates with multiple partners; founded 2003, headquartered in Dublin.

Company score

Sentiment: 0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.38; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive